These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3041132)

  • 1. Angiotensin-converting enzyme inhibitors.
    Weinberger MH
    Med Clin North Am; 1987 Sep; 71(5):979-90. PubMed ID: 3041132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin converting enzyme inhibitors and moderate hypertension.
    McAreavey D; Robertson JI
    Drugs; 1990 Sep; 40(3):326-45. PubMed ID: 2226219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system.
    Scheen AJ
    Drugs; 2004; 64(22):2537-65. PubMed ID: 15516153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin converting enzyme inhibitors enhance the antihypertensive efficacy of diuretics and blunt or prevent adverse metabolic effects.
    Weinberger MH
    J Cardiovasc Pharmacol; 1989; 13 Suppl 3():S1-4. PubMed ID: 2474093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors in hypertension: a review.
    Salvetti A; Pedrinelli R; Arzilli F; Abdel-Haq B; Magagna A; Lucarini A; Graziadei L; Nuccorini A; Taddei S
    Int J Clin Pharmacol Res; 1985; 5(6):429-38. PubMed ID: 3005182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension.
    Motwani JG
    J Renin Angiotensin Aldosterone Syst; 2002 Jun; 3(2):72-8. PubMed ID: 12228846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptides as targets for antihypertensive drug development.
    Hedner T; Sun X; Junggren IL; Pettersson A; Edvinsson L
    J Hypertens Suppl; 1992 Dec; 10(7):S121-32. PubMed ID: 1291647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Angiotensin II antagonists versus ACE inhibitors in the treatment of raised blood pressure].
    Andersen RS; Christensen S
    Ugeskr Laeger; 2001 Dec; 163(50):7036-9. PubMed ID: 11794033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New angiotensin converting enzyme inhibitors. Their role in the management of hypertension.
    Laragh JH
    Am J Hypertens; 1990 Nov; 3(11):257S-265S. PubMed ID: 2261144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological basis of antihypertensive drug therapy].
    Kolck UW; Zaugg CE; Erne P
    Praxis (Bern 1994); 2004 May; 93(20):847-56. PubMed ID: 15195836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is aliskiren superior to inhibitors of angiotensin-converting enzyme and angiotensin receptor blockers in renin-angiotensin system blockade?
    Gerc V; Buksa M; Loza V; Kulic M
    Med Arh; 2009; 63(6):343-9. PubMed ID: 20380117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experience with angiotensin II antagonists in hypertensive patients.
    Waeber B; Burnier M; Nussberger J; Brunner HR
    Clin Exp Pharmacol Physiol; 1996 Sep; 23 Suppl 3():S142-6. PubMed ID: 21143288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.
    Bramlage P; Schmieder RE; Gitt AK; Baumgart P; Mahfoud F; Buhck H; Ouarrak T; Ehmen M; Potthoff SA;
    Trials; 2015 Dec; 16():581. PubMed ID: 26686682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibitors. A safe option for hypertension and congestive heart failure.
    Amadio P; Amadio PB; Cummings DM
    Postgrad Med; 1990 Jan; 87(1):223-6, 231-2, 235-43. PubMed ID: 2404266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects.
    Katragadda S; Arora RR
    Am J Ther; 2010; 17(1):e11-23. PubMed ID: 20090429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.